Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Gartrell

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Urology|July 7, 2023
Reply by AuthorsAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Cancer|June 19, 2012
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapyAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|May 14, 2024
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature ReviewBenjamin A Gartrell, Angaja Phalguni, Paulina Bajko, et al.
The Journal of Urology|June 23, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). ReplyAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
World Journal of Urology|May 25, 2012
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United StatesAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|February 21, 2023
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder CancerBrant A Inman, Noah M Hahn, Kelly Stratton, et al.
Clinical Genitourinary Cancer|June 2, 2012
Trends in the use of cytoreductive nephrectomy in the United StatesChe-Kai Tsao, Alexander C Small, Erin L Moshier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2026
An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomyLuke T Nordquist, Jack R Andrews, Phillip H Kuo, et al.
World Journal of Urology|December 11, 2012
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysisChe-kai Tsao, Alexander C Small, Max Kates, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Urology|July 7, 2023
Reply by AuthorsAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Cancer|June 19, 2012
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapyAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|May 14, 2024
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature ReviewBenjamin A Gartrell, Angaja Phalguni, Paulina Bajko, et al.
The Journal of Urology|June 23, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). ReplyAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
World Journal of Urology|May 25, 2012
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United StatesAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|February 21, 2023
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder CancerBrant A Inman, Noah M Hahn, Kelly Stratton, et al.
Clinical Genitourinary Cancer|June 2, 2012
Trends in the use of cytoreductive nephrectomy in the United StatesChe-Kai Tsao, Alexander C Small, Erin L Moshier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2026
An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomyLuke T Nordquist, Jack R Andrews, Phillip H Kuo, et al.
World Journal of Urology|December 11, 2012
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysisChe-kai Tsao, Alexander C Small, Max Kates, et al.
Pageof 6